Dixon Mitchell Investment Counsel Inc. Buys 679,919 Shares of Certara, Inc. $CERT

Dixon Mitchell Investment Counsel Inc. lifted its stake in Certara, Inc. (NASDAQ:CERT) by 78.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,546,299 shares of the company’s stock after purchasing an additional 679,919 shares during the period. Dixon Mitchell Investment Counsel Inc. owned 0.97% of Certara worth $13,623,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its stake in shares of Certara by 2,733.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after purchasing an additional 2,870 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after acquiring an additional 1,175 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Certara by 499.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after acquiring an additional 4,930 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Certara in the second quarter valued at approximately $83,000. Finally, Curated Wealth Partners LLC bought a new stake in shares of Certara in the fourth quarter valued at approximately $89,000. 73.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CERT shares. Craig Hallum cut their target price on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. Barclays decreased their price objective on Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. TD Cowen reiterated a “buy” rating on shares of Certara in a report on Thursday, February 26th. Morgan Stanley dropped their price target on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus target price of $8.85.

Certara Stock Performance

NASDAQ CERT opened at $5.20 on Friday. The company has a 50-day simple moving average of $5.58 and a two-hundred day simple moving average of $7.19. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12-month low of $4.45 and a 12-month high of $13.88. The firm has a market cap of $808.96 million, a price-to-earnings ratio of -52.00 and a beta of 1.49.

Certara (NASDAQ:CERT) last posted its earnings results on Monday, May 11th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to analysts’ expectations of $106.13 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The business’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities analysts forecast that Certara, Inc. will post 0.24 EPS for the current year.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.